Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe symbols : Myov save search
Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet
Published: 2022-10-27 (Crawled : 17:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.26%
gemtesa sciences publication
Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting
Published: 2022-05-13 (Crawled : 17:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 2.9%
H: 5.64%
C: 4.06%
uro-902 sciences phase 2b
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
Published: 2022-05-09 (Crawled : 11:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -10.28%
H: 0.0%
C: 0.0%
orgovyx europe license cancer prostate cancer
ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION
Published: 2022-05-06 (Crawled : 13:20) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -1.71%
H: 0.0%
C: 0.0%
hypertension potential
Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
Published: 2022-03-22 (Crawled : 18:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.15%
H: 6.94%
C: 6.13%
gemtesa risk therapeutics bladder
Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 1.16%
H: 5.97%
C: 4.13%
health thc conference j.p. morgan healthcare conference
Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 1.41%
H: 2.2%
C: 1.49%
conference
Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
Published: 2021-08-04 (Crawled : 17:00) - biospace.com/
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.77%
H: 3.56%
C: -2.29%
positive
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
Published: 2021-07-20 (Crawled : 07:00) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 1.27%
H: 1.7%
C: -0.4%
treatment europe women approval
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.